Testing effectiveness (Phase 2)Active Not RecruitingNCT06242834
What this trial is testing
Pembrolizumab and Tazemetostat to Overcome Immune Tolerance Following ASCT or CAR T-cell Therapy in Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma
Who this might be right for
B-Cell Non-Hodgkin Lymphoma
Northwestern University 11